Skip to content

Shock-Waves to Treat Fibromyalgia Pain

Treating Fibromyalgia Pain With Shock-Waves: a Randomized Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03088215
Acronym
SWPW-FPS
Enrollment
40
Registered
2017-03-23
Start date
2017-10-20
Completion date
2018-11-20
Last updated
2017-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Sensitization, Fibromyalgia, MSK: Chronic Pain Syndromes (E.G. Fibromyalgia), Myofascial Pain Syndrome

Keywords

Trigger Point Pain, Myofascial, shock-waves, extracorporeal shock-wave treatment (ESWT), pain, trigger point, referred pain

Brief summary

Fibromyalgia pain syndrome is a common debilitating condition which associates mainly generalised pain, emotional distress and cognitive symptoms. The etiology is unknown, and no specific treatment exists so far. Lately, shock-waves have been used successfully to treat painful skeletal muscle, tendons and fascia, the investigators therefore hypothesize that shock-waves could be useful in alleviating Fibromyalgia pain. Two similar groups of participants bearing the condition will be prospectively compared. The first group will benefit from the application of shock-waves weekly for 12 weeks, the second will not. The investigators intend to study if there is any difference in pain and quality of life between the two groups at the end of the three months.

Detailed description

Fibromyalgia Pain Syndrome (FPS) is a common debilitating condition which associates mainly generalised pain, emotional distress and cognitive symptoms. The etiology is unknown, and no specific treatment exists so far. It bears some similarities with another, more localised clinical condition : the Myofascial Pain Syndrome (MPS), which results in pain caused by, amongst others, muscular trigger points. Lately, FPS and MPS have both been classified as belonging to a new, larger entity : Central Sensitivity Syndromes (CSS), in which a strong and chronic peripheral sensitive stimulus (like musculoskeletal pain) is believed to induce, after some time, an enhanced response of the central nervous system (CNS) towards that same stimulus, with the result that the stimulus will be felt more powerfully (central sensitization, CS). This is secondary to neuroplastic changes in the CNS, which are reversible to some extent. Since shock-waves are effective to treat pain in MPS (by eliminating trigger points and thus restoring muscle and tissue function), and since MPS and FPS could be linked by a common pathophysiologic mechanism (CSS), the investigators hypothesize that shock waves could be beneficial in treating pain in FPS. Two groups of 20 participants will be prospectively compared over a three month's period. One group will receive shock-waves on painful muscular areas weekly for 12 weeks, the other group will not receive any shock-waves. The investigators intend to study if there is any difference in pain and quality of life after the end of the three months.

Interventions

DEVICEshock-waves

Application of shock-waves (radial and focused)

Sponsors

Projet Suisse d'Assistance Medicale
CollaboratorOTHER
Dr Yves JACOT, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* American College of Rheumatology 2011 diagnostic criteria for Fibromyalgia met * Aged between 18 and 65 years * Informed Consent Form signed

Exclusion criteria

* Known skeletal pathologies such as osteoarthritis of major joints and / or vertebrae, inflammatory states involving bones, joints, tendons or muscles, or previous heavy trauma directly causing the pain * Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, carcinoma, cardiovascular disease, pulmonary insufficiency, etc.), * Coagulopathies, anticoagulant or corticosteroid based medication, thrombosis. * Psychological distress, psychosis, dementia * Known or suspected non-compliance, drug or alcohol abuse, * Pregnancy * Enrolment of the investigator, his/her family members, employees and other dependent or vulnerable persons

Design outcomes

Primary

MeasureTime frameDescription
Pain VAS12 weeksHorizontal visual analog scale for pain (pain intensity)

Secondary

MeasureTime frameDescription
Apparent change in successive Pain Body Maps over time12 weeksParticipants will be distributed successive body map models where they are asked to draw the precise location and extension of the areas where they experience pain. The maps completed at every given time will then be compiled for each group (by computer). The final compiled pictures will be visually compared between each group. So far, it is not planned to do measurements (such as surface, etc...), the maps will serve mainly illustrate differences in pain extension between the two groups.
Interference scale of the Body Pain Index (BPI)12 weeksQuestionnaire reflecting interference of pain in quality of life
Patient Global Impression of Change scale (PGIC)12 weeksQuestionnaire reflecting effects of intervention (or non-intervention)from the participant's point of view

Other

MeasureTime frameDescription
American College of Rheumatology (ACR) diagnostic criteria 2011 for Fibromyalgia12 weeksServes to assess if participants in intervention arm still meet the diagnostic criteria for Fibromyalgia at the end of the study

Contacts

Primary ContactDr Yves JACOT, MD
yves.jacot@cmvesenaz.ch004179 703 24 72

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026